Do Big Money Love Islet Sciences Inc (NASDAQ:ONCE), Sentiment at 1.43

May 16, 2018 - By Joshua Cleveland

Spark Therapeutics, Inc. (NASDAQ:ONCE) Corporate Logo

Positions for Islet Sciences Inc (NASDAQ:ONCE)

“Big money sentiment for Islet Sciences Inc (NASDAQ:ONCE) in 2017 Q4 decreased to 1.43, revealed SEC filings. So its down -1.51, from 2017Q3’s 2.94. 96 hedge funds increased or opened new holdings, while 67 cut down and sold their equity positions in Islet Sciences Inc so the sentiment worsened. These funds own 35.76 million shares, that’s up from 33.64 million shares in 2017Q3. Funds holding Islet Sciences Inc in top 10 changed to 0 from 1 for a decrease of 1. In total 41 funds closed positions, 26 reduced and 55 increased. Also 41 funds bought new Islet Sciences Inc stakes.

Biggest Islet Sciences Inc Shareholders

As of 2017 Q4 Great Point Partners Llc has 3.61% invested in Islet Sciences Inc. Islet Sciences Inc’s shareholder Rock Springs Capital Management Lp owns 615,000 shares as of 2017 Q4. Furthermore, Eventide Asset Management Llc reported 324,000 shares in Islet Sciences Inc equivalent to 0.87% of its US long equity exposure. Baker Bros. Advisors Lp revealed 1.38 million shares position in Islet Sciences Inc. The Israel-based fund Sphera Funds Management Ltd. holds 100,000 shares or 0.6% of their US long equity exposure.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.The firm is worth $2.92 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.Last it reported negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Ticker’s shares touched $78.015 during the last trading session after 0.91% change.Currently Spark Therapeutics, Inc. is uptrending after 21.52% change in last May 16, 2017. ONCE has 213,077 shares volume. ONCE outperformed by 9.97% the S&P 500.

On August, 1 is anticipated Spark Therapeutics, Inc. (NASDAQ:ONCE)’s earnings report, RTT reports. Analysts have anticipation on stock’s EPS of $-0.41. That’s up 78.31 % from last year’s $-1.89 EPS. Analysts at Wall Street see Spark Therapeutics, Inc.’s -67.20 % EPS growth compared to $-1.25 EPS for previous quarter.

Vanguard Group accumulated 2.58 million shs or 0.01% of the stock. Fincl Architects Inc stated it has 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Pub Employees Retirement Association Of Colorado has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Winslow Evans And Crocker reported 0% stake. University Of Notre Dame Du Lac owns 0.41% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 38,371 shs. Tudor Et Al has 8,864 shs for 0.01% of their capital. Fil Limited stated it has 87,218 shs. The New York-based Citigroup has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Wells Fargo & Com Mn stated it has 253,563 shs or 0% of all its holdings. Tekla Cap Ltd Liability Corp has invested 0.08% of its capital in Spark Therapeutics, Inc. (NASDAQ:ONCE). Ameritas Invest Prns holds 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 2,290 shs. Fmr Lc has 0.03% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Moreover, Tiaa Cref Investment Mngmt Limited Co has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Balyasny Asset Mngmt Limited Com invested in 58,180 shs. Ipswich Invest owns 0.2% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 9,334 shs.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

In total 18 analysts cover Spark Therapeutics (NASDAQ:ONCE). “Buy” rating has 10, “Sell” are 1, while 7 are “Hold”. 56% are bullish. 35 are the (NASDAQ:ONCE)’s analyst reports since December 11, 2017 according to StockzIntelligence Inc. On Thursday, March 8 Credit Suisse maintained the shares of ONCE in report with “Outperform” rating. On Tuesday, January 16 the stock has “Underperform” rating by Wedbush. On Tuesday, May 1 JP Morgan maintained the shares of ONCE in report with “Neutral” rating. In Monday, May 7 report Leerink Swann maintained it with “Hold” rating and $7400 target. On Wednesday, February 21 the firm has “Buy” rating given by Stifel Nicolaus. On Monday, April 23 Chardan Capital Markets downgraded the shares of ONCE in report to “Neutral” rating. On Monday, February 12 the rating was initiated by Mizuho with “Buy”. On Thursday, January 25 the firm has “Overweight” rating by Barclays Capital given. On Wednesday, January 24 the firm has “Buy” rating by BMO Capital Markets given. On Wednesday, May 9 BMO Capital Markets maintained the shares of ONCE in report with “Outperform” rating.

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were announced by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “Spark Therapeutics 2018 Q1 – Results – Earnings Call Slides” as a title and was announced on May 08, 2018. The next is “Spark Therapeutics’ (ONCE) CEO Jeff Marrazzo on Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. And last was announced on May 14, 2018, called “Genomic Medicine: Catch The Gene Therapy Wave”.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: